Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Magnetic imaging agent
Reexamination Certificate
1999-06-18
2001-11-27
Jones, Dameron L. (Department: 1619)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Magnetic imaging agent
C424S001110, C424S009100, C424S009400, C424S009500, C536S027600
Reexamination Certificate
active
06322771
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to methods and compositions for carrying out pharmacological stress imaging with certain alkynyladenosine compounds.
BACKGROUND OF THE INVENTION
Pharmacologic stress is increasingly being employed as an alternative to exercise stress in patients undergoing nuclear or echocardiographic imaging for the detection of coronary artery disease. It is frequently induced with adenosine or dipyridamole in patients with suspected coronary artery disease prior to imaging with radiolabeled perfusion tracers such as
201
Tl or
99m
Tc-sestamibi, or by echocardiography. In 1999, it is predicted that 1.7 million patients will be studied using pharmacologic stress imaging in the United States alone. The advantage of pharmacologic vasodilatation over exercise is that pharmacologic stress results in a repeatable level of coronary flow increase which is not dependent upon patient fitness and/or motivation. The sensitivity and specificity for the detection of coronary artery disease is high for both adenosine and dipyridamole stress perfusion imaging, ranging between 85-90%.
A major disadvantage of using adenosine or dipyridamole stress is that there is an unusually high incidence of adverse side effects with both of these vasodilators. In one prospective study of 9,256 patients that underwent adenosine stress radionuclide imaging, 82% experienced adverse side effects (M. D. Cequiera et al.,
J. Am. Coll. Cardiol.,
23, 384 (1994)). The most common side effects were flushing (37%), chest pain (35%), shortness of breath or dyspnea (35%), headache (14%), ECG changes (9%), and A-V conduction block (8%). A similar side effect profile has been reported for dipyridamole. In a study by A. Ranhosky et al. (
Circulation,
81, 1205 (1990)) with 3,911 patients receiving dipyridamole, 19.7% experienced chest pain, 12% had headaches, and 8% had ST-segment changes on their ECG. In addition to these side effects, a substantial number of patients experience a marked decrease in blood pressure during the administration of these vasodilators. In another 3,715 patients receiving dipyridamole, the mean systolic blood pressure fell by 14 mm Hg with 11% of the patients demonstrating a >20% drop in systolic blood pressure (J. Lette et al.,
J. Nucl. Cardiol.,
2, 3 (1995)).
Whereas the desired coronary vasodilatation is mediated by the stimulation of the adenosine A
2A
receptor by adenosine, most of the side effects are caused by stimulation of the other three adenosine receptor subtypes: A
1
, A
2 B
, and A
3
. While a pre-treatment strategy with an adenosine receptor antagonist may reduce some side effects and improve patient comfort and safety, a simpler strategy would be to design a vasodilator that has little or no affinity for the adenosine A
1
, A
2B
or A
3
receptor subtypes, but that selectively stimulates the A
2A
receptors. In fact, there has been progressive development of compounds that are more and more potent and/or selective as agonists of A
2A
adenosine receptors (AR) based on radioligand binding assays and physiological responses. Initially, compounds with little or no selectivity for A
2A
receptors were developed, such as adenosine itself or 5′-carboxamides of adenosine, such as 5′-N-ethylcarboxamidoadenosine (NECA) (B. N. Cronstein et al.,
J. Immnol.,
135, 1366 (1985)). Later, it was shown that addition of 2-alkylamino substituents increased potency and selectivity, e.g., CV1808 and CGS21680 (M. F. Jarvis et al.,
J. Pharmacol. Exp. Ther.,
251, 888 (1989)). 2-Alkoxy-substituted adenosine derivatives such as WRC-0090 are even more potent and selective as agonists at the coronary artery A
2A
receptor (M. Ueeda et al.,
J. Med. Chem.,
34, 1334 (1991)).
Olsson et al. (U.S. Pat. No. 5,140,015) disclose certain adenosine A
2
receptor agonists of formula:
wherein C(X)BR
2
can be CH
2
OH and R
1
can be alkyl- or alkoxyalkyl. The compounds are disclosed to be useful as vasodilators or an antihypertensives.
Linden et al. (U.S. Pat. No. 5,877,180) is based on the discovery that certain inflammatory diseases, such as arthritis and asthma, may be effectively treated by the administration of compounds which are selective agonists of A
2A
adenosine receptors, preferably in combination with a Type IV phosphodiesterase inhibitor. An embodiment of the Linden et al. invention provides a method for treating inflammatory diseases by administering an effective amount of an A
2A
adenosine receptor of the following formula:
wherein R and X are as described in the patent.
Mohiuddin et al. (U.S. Pat. No. 5,070,877) discloses the use of the relatively nonspecific adenosine analog, 2-chloroadenosine (Cl-Ado), as a pharmacological stressor. However, the Cl-Ado analog is actually a more potent activator of A
1
adenosine receptors than of A
2A
adenosine receptors and, thus, is likely to cause side effects due to activation of A
1
receptors on cardiac muscle and other tissues causing effects such as “heart block.”
G. Cristalli (U.S. Pat. No. 5,593,975) discloses 2-arylethynyl, 2-cycloalkylethynyl or 2-hydroxyalkylethynyl derivatives, wherein the riboside residue is substituted by carboxy amino, or substituted carboxy amino (R
3
HNC(O)—). 2-Alkynylpurine derivatives have also been disclosed in Miyasaka et al. (U.S. Pat. No. 4,956,345), wherein the 2-alkynyl group is substituted with (C
3
-C
16
)alkyl. The '975 compounds are disclosed to be vasodilators and to inhibit platelet aggregation, and thus to be useful as anti-ischeric, anti-atherosclerosis and anti-hypertensive agents.
R. A. Olsson et al. (U.S. Pat. No. 5,278,150) disclose selective adenosine A
2
receptor agonists of the formula:
wherein Rib is ribosyl, R
1
can be H and R
2
can be cycloalkyl. The compounds are disclosed to be useful for treating hypertension, atherosclerosis and as vasodilators.
These 2-alklylhydrazino adenosine derivatives, such as 2-cyclohexyl methylidene hydrainoadenosine (WRC-0474), have also been evaluated as agonists at the coronary artery A
2A
receptor (K. Niiya et al.,
J. Med. Chem.,
35, 4557 (1992)). WRC-0474 has further been evaluated in the dog model for use in pharmacological stress thallium imaging. See, D. K. Glover et al.,
Circulation,
94, 1726 (1996).
Thus, a continuing need exists for selective A
2
adenosine receptor agonists useful for use as pharmacological stressors in stress imaging or in other ventricular function imaging techniques, that preferably have reduced side effects, while being chemically stable and short-acting.
SUMMARY OF THE INVENTION
The present invention comprises compounds and methods of their use for detecting the presence of, and assessing the severity of myocardial perfusion abnormalities, such as due to coronary artery stenosis in a mammal, such as a human or domestic animal. Preferably, the compounds of the invention are used as pharmacological stress-inducing agents or stressors that are useful in pharmacological stress imaging for the detection and assessment of coronary artery stenosis due to coronary artery disease. The preferred compounds of the invention are potent and selective at A
2A
adenosine receptors, but are also short-acting, so that they are rapidly cleared by the body following the imaging process.
The present compounds comprise a novel class of 2-alkynyladenosine derivatives, substituted at the ethyne position by substituted cycloalkyl moieties. Preferably, the riboside residue is substituted at the 5′-position (“X”) by an N-alkyl-(or N-cycloalkyl)aminocarbonyl moiety. Thus, the present invention provides a method for detecting the presence and severity of coronary artery stenosis in a mammal, such as a human subject, comprising
(1) administering an amount of one or more compounds of the general formula (I):
wherein
(a) each R is individually hydrogen, C
1
-C
6
alkyl, C
3
-C
7
cycloalkyl, phenyl or phenyl(C
1
-C
3
)-alkyl;
(b) X is —CH
2
OH, —CO
2
R
2
, —OC(O)R
2
CH
2
OC(O)R
2
or C(O)NR
3
R
4
;
(c) each of R
2
, R
3
and R
4
is individually H, C
1-6
-alkyl; C
1-6
-alkyl substituted wi
Beller George A.
Glover David K.
Linden Joel M.
MacDonald Timothy
Jones Dameron L.
Schwegman Lundberg Woessner & Kluth P.A.
University of Virginia Patent Foundation
LandOfFree
Induction of pharmacological stress with adenosine receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Induction of pharmacological stress with adenosine receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Induction of pharmacological stress with adenosine receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2612481